FilingReader Intelligence
Guilin Sanjin's subsidiary gets approval for BC006 clinical trial
May 5, 2025 at 05:11 PM UTC•By FilingReader AI
Guilin Sanjin Pharmaceutical (SZSE:002275) announced that its holding subsidiary, Baichuan Biopharmaceutical Technology (Shanghai) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its BC006 monoclonal antibody injection. The approval pertains to a new indication for idiopathic pulmonary fibrosis.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002275•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Guilin Sanjin Pharmaceutical publishes news
Free account required • Unsubscribe anytime